🏢 官网IRDYNCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:47:10时区推断·⟳ 抓取 04:50:32·⚡ 决策 07-22 04:53:21 +2m49s·97.5 天前
Dyne Therapeutics宣布拟增发3亿美元普通股
Dyne Therapeutics（DYN.US）盘后宣布拟公开发行3亿美元普通股，并可能额外授予4500万美元超额配售权，所有股份由公司出售，短期核心影响是股本稀释。
📄 原文DYN↗ 原文
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Skip to main navigation Skip to main content Open navigation About Us FORCE TM Platform Pipeline Physicians Patients In…
不做 Dyne Therapeutics（DYN.US）
事件方向偏空，但拟发行尚未定价、近期药物监管正面叙事可能对冲稀释压力，且未确认可借券，不能通过做空执行红线；不反手做多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-21 · 扩散 low · price-in 风险 low ↗
关键理由
- Dyne Therapeutics（DYN.US）盘后宣布拟公开发行3亿美元普通股，并可能额外授予4500万美元超额配售权，所有股份由公司出售，短期核心影响是股本稀释。
- DYN.US最新收盘价23.83美元，近20日上涨14.18%、距52周高点仅约4.68%，融资公告出现在股价相对高位，容易被市场解读为趁窗口补现金。
- 同类美股临床/基因药物公司公开发行先例中，+3日中位数为-2.48%、胜率20%，方向偏弱但次日反应不稳定。
主要风险
- 公司7月20日已有DMD候选药BLA受理/优先审评相关正面叙事，增发也会延长现金跑道，可能抵消部分稀释压力。
- 本次仍是proposed offering，未披露最终定价、折价率和发行股数；若定价强、承销完成顺利，空头边际可能快速钝化。
反向证据
- 做空前查反向 · 来源 kb_search · 日期 2026-07-20 · 影响 weakens
内部库命中DYN 2026 Earnings Report/8-K线索，显示公司近期存在候选药监管进展相关正面背景，削弱单纯融资利空的空头确定性。
检索:Dyne Therapeutics DYNE-251 DYNE-101 recent positive BLA priority review cash balance 2026 原文 ↗ - 做空前查反向 · 来源 kb_search · 日期 2026-07-20 · 影响 weakens
未命中可确认借券可用量的信息；按做空红线，无法把负面判断升级为可执行空单。
检索:DYN Dyne Therapeutics short interest borrow availability public offering bearish positive FDA priority review July 2026 原文 ↗
历史先例(按相似度)
- 相似度 8/10 BEAM.US 2024-02-29 Beam Therapeutics公开发行普通股融资。 原文 ↗
BEAM.US公告后+1日+0.89%、+3日-2.48%、+5日-6.41%。
相似度依据:同为临床/基因药物公司公开发行，机制和投资者反应窗口接近。 - 相似度 7/10 CRSP.US 2024-01-03 CRISPR Therapeutics宣布普通股承销发行，稀释压力与补充资金并存。 原文 ↗
CRSP.US公告后+1日-0.99%、+3日+0.21%、+5日+1.25%。
相似度依据:同为美股基因/生物科技公司公开发行，融资稀释机制相近，但公司阶段和事件背景不同。 - 相似度 7/10 NTLA.US 2023-06-27 Intellia Therapeutics公开发行普通股融资。 原文 ↗
NTLA.US公告后+1日+3.31%、+3日-0.05%、+5日-0.86%。
相似度依据:同为临床阶段基因编辑公司公开发行普通股，稀释机制相近。 - 相似度 7/10 EDIT.US 2023-01-05 Editas Medicine宣布普通股公开发行定价。 原文 ↗
EDIT.US公告后+1日+0.56%、+3日-7.37%、+5日-0.78%。
相似度依据:同为基因编辑公司普通股公开发行定价，适合观察稀释后短线反应。 - 相似度 6/10 RXRX.US 2024-02-28 Recursion承销公开发行A类普通股。 原文 ↗
RXRX.US公告后+1日+4.02%、+3日-4.95%、+5日-12.52%。
相似度依据:同为美股生物科技融资，但业务类型和投资者基础不同。
工具调用 · 历史记录,结果未知(6 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- search_case_library · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
- event_study · 结果未知
原文全文
展开原文 · 7,467 字
Skip to main navigation
Skip to main content
Open navigation
About Us
FORCE TM Platform
Pipeline
Physicians
Patients
Investors & Media
Culture & Careers
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
about-us
Overview
Scientific publications & presentations
force™-platform
Overview
Zeleciment rostudirsen (DYNE-251)
Zeleciment basivarsen (DYNE-101)
DYNE-302
pipeline
physicians
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
patients
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
investors--media
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
culture--careers
Stay in Touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Poised to address unmet need in neuromuscular diseases and
positioned for growth
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
July 21, 2026
PDF Version
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com ; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com ; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the proposed underwritten public offering, the anticipated terms of the proposed offering, market and other conditions relating to the offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement to be filed with the SEC, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
back to news
Print
Contact IR
RSS
Email Alerts
Stay in touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Privacy Policy
© 2026 Dyne Therapeutics, Inc.
You are now leaving
the Dyne Therapeutics corporate website
Continue Stay on page
Skip to main content
Open navigation
About Us
FORCE TM Platform
Pipeline
Physicians
Patients
Investors & Media
Culture & Careers
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
about-us
Overview
Scientific publications & presentations
force™-platform
Overview
Zeleciment rostudirsen (DYNE-251)
Zeleciment basivarsen (DYNE-101)
DYNE-302
pipeline
physicians
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
patients
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
investors--media
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
culture--careers
Stay in Touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Poised to address unmet need in neuromuscular diseases and
positioned for growth
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
July 21, 2026
PDF Version
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com ; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com ; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the proposed underwritten public offering, the anticipated terms of the proposed offering, market and other conditions relating to the offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement to be filed with the SEC, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
back to news
Contact IR
RSS
Email Alerts
Stay in touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Privacy Policy
© 2026 Dyne Therapeutics, Inc.
You are now leaving
the Dyne Therapeutics corporate website
Continue Stay on page
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。